Gonadorelin

This article is about gonadorelin (GnRH) as a medication. For its role as a hormone, see Gonadotropin-releasing hormone.
Gonadorelin
Clinical data
Trade namesFactrel, HRF, Kryptocur, Lutrelef, Lutrepulse, Relefact, others
Other namesAbbott 41070; AY-24031; Hoe-471; RU-19847
Routes of
administration		intravenous, subcutaneous[1]
Drug classGnRH analogue; GnRH agonist; Progonadotropin
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismHydrolysis[1]
Elimination half-life10–40 minutes[1]
Identifiers
  • (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.046.852 Edit this at Wikidata
Chemical and physical data
FormulaC55H75N17O13
Molar mass1182.311 g·mol−1
3D model (JSmol)
  • CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6
  • InChI=1S/C55H75N17O13/c1-29(2)19-38(49(80)67-37(9-5-17-60-55(57)58)54(85)72-18-6-10-43(72)53(84)62-25-44(56)75)66-46(77)26-63-47(78)39(20-30-11-13-33(74)14-12-30)68-52(83)42(27-73)71-50(81)40(21-31-23-61-35-8-4-3-7-34(31)35)69-51(82)41(22-32-24-59-28-64-32)70-48(79)36-15-16-45(76)65-36/h3-4,7-8,11-14,23-24,28-29,36-43,61,73-74H,5-6,9-10,15-22,25-27H2,1-2H3,(H2,56,75)(H,59,64)(H,62,84)(H,63,78)(H,65,76)(H,66,77)(H,67,80)(H,68,83)(H,69,82)(H,70,79)(H,71,81)(H4,57,58,60)/t36-,37-,38-,39-,40-,41-,42-,43-/m0/s1
  • Key:XLXSAKCOAKORKW-AQJXLSMYSA-N

Gonadorelin is a gonadotropin-releasing hormone agonist (GnRH agonist) which is used in fertility medicine and to treat amenorrhea and hypogonadism.[2][3][4][5][6][7] It is also used in veterinary medicine.[3][5] The medication is a form of the endogenous GnRH and is identical to it in chemical structure.[2][3][5][7] It is given by injection into a blood vessel or fat or as a nasal spray.[5][1][7]

  1. ^ a b c d "Gonadorelin".
  2. ^ a b Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 745–. ISBN 978-1-4757-2085-3.
  3. ^ a b c Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 499–. ISBN 978-3-88763-075-1.
  4. ^ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 136–. ISBN 978-94-011-4439-1.
  5. ^ a b c d "Gonadorelin injectable Uses, Side Effects & Warnings".
  6. ^ Shao WM, Bai WJ, Chen YM, Liu L, Wang YJ (August 2014). "[Micropump infusion of gonadorelin in the treatment of hypogonadotropic hypogonadism in patients with pituitary stalk interruption syndrome: cases analysis and literature review]". Beijing da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences (in Chinese). 46 (4): 642–645. PMID 25131486.
  7. ^ a b c Köhn FM, Schill WB (17 July 2017). "Hormone Substitution in Male Infertility". In Allahbadia GN, Chawla MM, Das RB, Garcia EV, Gandhi G, Merchant R (eds.). The Art & Science of Assisted Reproductive Techniques (ART). JP Medical Ltd. pp. 731–. ISBN 978-93-86322-82-1.